4basebio PLC H1 2024 Half-Year Results Report

4basebio PLC, an innovation-driven biotechnology company, reported H1 2024 results with revenues exceeding £300k and an order book above £600k, demonstrating strong growth in synthetic DNA and GMP opportunities for advanced therapy medicinal products. The company announced a £40m investment and disclosed supply agreements with tier-one pharma for DNA production in mRNA vaccine manufacturing and first-in-human clinical trials. With increased headcount to 101 and five patent filings during 2024, 4basebio continues advancing its synthetic DNA platform and Hermes™ nucleic acid delivery platform.